Ubs Asset Management Americas Inc Vaxcyte, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 472,964 shares of PCVX stock, worth $33 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
472,964
Previous 408,274
15.84%
Holding current value
$33 Million
Previous $46.6 Million
16.94%
% of portfolio
0.01%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding PCVX
# of Institutions
350Shares Held
130MCall Options Held
539KPut Options Held
253K-
Vanguard Group Inc Valley Forge, PA12MShares$836 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$739 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$694 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$607 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$434 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.14B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...